Popular GLP-1 weight-loss medications may contribute to lower mortality for people with colon cancer, according to study results published in Cancer Investigation
In T1DM, for instance, genetic variations at risk loci are strongly associated with characteristic inflammatory responses and distinct patterns of immune dysregulation (Ma et al., 2024)
They will adjust your semaglutide dose based on your other medicines and health needs
If you were to buy into the marketing hype around GLP-1 drugs like Wegovy and Zepbound, you might believe they are a panacea for every patient who needs to lose weight, regardless of BMI
Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)